文献速递脊柱关节炎

生物制剂对强直性脊柱炎患者健康相关生活质量的影响:随机对照试验的系统综述与Meta分析

Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: A systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Semin Arthritis Rheum · 2022-03-19

该系统综述与Meta分析纳入16项随机对照试验共3481例放射学轴性脊柱关节炎患者,比较生物制剂与安慰剂对健康相关生活质量的影响,安慰剂对照及治疗盲法时长12至24周。生物制剂治疗在SF-36、EQ-5D和ASQoL三个量表上均较安慰剂显著改善生活质量,作者结论为生物制剂治疗与生活质量的显著改善相关。

要点

  • 纳入16项RCT共3481例r-axSpA患者,生物制剂较安慰剂显著改善SF-36 PCS、MCS、EQ-5D及ASQoL。
  • SF-36 PCS合并均数差4.39(95%CI 3.24至5.54,P<0.001),异质性高(I²=79%)。
  • ASQoL合并均数差-2.45(95%CI -3.21至-1.70,P<0.001),三个HRQoL量表结果一致。

核心结论

  • 生物制剂治疗与r-axSpA患者生活质量的显著改善相关,且三种健康相关生活质量量表的结果一致。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase和Clinicaltrials.gov数据库至2022年2月,纳入报告bDMARDs治疗r-axSpA健康相关生活质量结局的随机对照试验。
  • 共纳入16项RCT、3481例参与者,批准的bDMARD治疗包括五种TNF抑制剂(英夫利西单抗、依那西普、阿达木单抗、戈利木单抗和培塞利珠单抗)和两种IL-17A抗体药物(司库奇尤单抗和依奇珠单抗)。
  • 安慰剂对照及治疗盲法时长为12至24周,采用I²评估研究间异质性。

主要发现

  • 与安慰剂相比,bDMARD治疗在SF-36、EQ-5D和ASQoL三个量表上均与健康相关生活质量的显著改善相关。
  • SF-36 PCS、SF-36 MCS、EQ-5D和ASQoL较基线变化的合并均数差分别为4.39(95%CI 3.24至5.54,P<0.001)、2.37(95%CI 1.25至3.49,P=0.003)、0.11(95%CI 0.07至0.14,P<0.001)和-2.45(95%CI -3.21至-1.70,P<0.001)。
  • 报告SF-36 PCS的研究间异质性高(I²=79%),报告SF-36 MCS、EQ-5D和ASQoL的研究间异质性分别为中等(I²=61%、34%和49%)。

关键数值与推荐

  • SF-36 PCS较基线变化的合并均数差为4.39(95%CI 3.24至5.54,P<0.001),异质性I²=79%。
  • SF-36 MCS较基线变化的合并均数差为2.37(95%CI 1.25至3.49,P=0.003),异质性I²=61%。
  • EQ-5D较基线变化的合并均数差为0.11(95%CI 0.07至0.14,P<0.001),异质性I²=34%。
  • ASQoL较基线变化的合并均数差为-2.45(95%CI -3.21至-1.70,P<0.001),异质性I²=49%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 报告SF-36 PCS的研究间异质性高(I²=79%)。
  • 报告SF-36 MCS、EQ-5D和ASQoL的研究间异质性分别为中等(I²=61%、34%和49%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the impact of novel biologic disease-modifying antirheumatic drugs (bDMARDs) with tumor necrosis factor (TNF) inhibitors or Interleukin-17A (IL-17A) antibody agents on health-related quality of life (HRQoL) outcomes in patients with radiographic axial spondyloarthritis (r-axSpA). METHODS: A literature search on PubMed, Embase, and Clinicaltrials.gov databases was performed through February 2022 to identify randomized controlled trials (RCTs) reporting HRQoL outcomes of bDMARDs for treatment of r-axSpA. Approved bDMARD therapy for r-axSpA included five TNF-inhibitors (infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol) and two IL-17A antibody agents (secukinumab, and ixekizumab). Heterogeneity (I2) was used to determine the variability between studies. RESULTS: Sixteen RCTs, involving 3481 participants, were included. The placebo-controlled and treatment blinded durations ranged from 12 to 24 weeks. Compared with the placebo, bDMARD therapy was associated with significant improvement in HRQoL measures with the 36-item Short Form Survey (SF-36), European Quality of Life-5 Dimensions (EQ-5D), and Ankylosing Spondylitis Quality of Life (ASQoL). The pooled mean differences of changes from baseline for the SF-36 Physical Component Score (PCS), SF-36 Mental Component Score (MCS), EQ-5D, and ASQoL were 4.39 [95% Confidence Interval (CI): 3.24 to 5.54, P < 0.001]; 2.37 (95%-CI: 1.25 to 3.49, P = 0.003); 0.11 (95%-CI: 0.07 to 0.14, P < 0.001); and -2.45 (95%-CI: -3.21 to -1.70, P < 0.001), respectively. Heterogeneity was high (I2 = 79%) among studies reporting SF-36 PCS, and moderate (I2 = 61%, 34%, and 49%) among studies reporting SF-36 MCS, EQ-5D, and ASQoL, respectively. CONCLUSIONS: Biologic therapy was associated with a significant improvement in quality of life in patients with r-axSpA. The results were consistent among all three measures of HRQoL outcomes.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Ho A, Younis I, Le QA, et al. Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: A systematic review and meta-analysis of randomized controlled trials. Semin Arthritis Rheum. 2022. PMID: 35339841. doi:10.1016/j.semarthrit.2022.151996

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。